Literature DB >> 35707151

Novel 6-Methoxy-3,4-dihydro-1H-isoquinoline Compounds for Treating Diabetes.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2022        PMID： 35707151      PMCID： PMC9190273          DOI： 10.1021/acsmedchemlett.2c00220

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  6 in total

Review 1.  Revisiting the concept of incretin and enteroendocrine L-cells as type 2 diabetes mellitus treatment.

Authors:  Kok-Hou Lok; Nicholas J Wareham; Rajesh Sreedharan Nair; Chee Wun How; Lay-Hong Chuah
Journal:  Pharmacol Res       Date:  2022-04-26       Impact factor: 7.658

Review 2.  Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review.

Authors:  Alessandro Mantovani; Christopher D Byrne; Giovanni Targher
Journal:  Lancet Gastroenterol Hepatol       Date:  2022-01-12

Review 3.  Phytochemicals modulate pancreatic islet β cell function through glucagon-like peptide-1-related mechanisms.

Authors:  Wanfang Zheng; Linghuan Li; Hanbing Li
Journal:  Biochem Pharmacol       Date:  2021-10-27       Impact factor: 5.858

Review 4.  Peptides in the regulation of glucagon secretion.

Authors:  Daniel B Andersen; Jens J Holst
Journal:  Peptides       Date:  2021-11-05       Impact factor: 3.750

Review 5.  Roles of glucose-dependent insulinotropic polypeptide in diet-induced obesity.

Authors:  Yusuke Seino; Yuji Yamazaki
Journal:  J Diabetes Investig       Date:  2022-05-11       Impact factor: 3.681

Review 6.  Glucagon-like peptide-1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?

Authors:  Tito Borner; Ian C Tinsley; Robert P Doyle; Matthew R Hayes; Bart C De Jonghe
Journal:  Br J Pharmacol       Date:  2021-09-14       Impact factor: 8.739
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.